References
- Bentley D, Young AM, Rowell L, et al. (2012). Evidence of a drug–drug interaction linked to inhibition of ester hydrolysis by orlistat. J Cardiovasc Pharmacol 60:390–6
- de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. (2002). Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159–65
- Derks M, Busse-Reid R, Kuhlmann O, Paehler A. (2010). [14C]-Dalcetrapib ADME following a single oral dose in healthy male subjects. Clin Pharmacol Ther 87:P1–47
- Derks M, Fowler S, Kuhlmann O. (2009). A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 31:586–99
- Downs JR, Clearfield M, Weis S, et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–22
- Gross G, Tardio J, Kuhlmann O. (2012). Solubility and stability of dalcetrapib in vehicles and biological media. Int J Pharm 437:103–9
- Heinig K, Bucheli F, Kuhlmann O, et al. (2012). Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 66:314–24
- Inazu A, Brown ML, Hesler CB, et al. (1990). Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234–8
- Kuhlmann O, Heinig K. (2011). Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica 41:430–6
- Lagrost L. (1994). Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta 1215:209–36
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–75
- Okamoto H, Yonemori F, Wakitani K, et al. (2000). A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203–7
- Park BK, Grabowski PS, Yeung JH, Breckenridge AM. (1982). Drug protein conjugates–I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat. Biochem Pharmacol 31:1755–60
- Phelan M, Anzures-Cabrera J, Carlile DJ, et al. (2013). Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol? Clin Pharmacokinet 52:255–65
- Sacks FM, Pfeffer MA, Moye LA, et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001–9
- Schwartz GG, Olsson AG, Abt M, et al. (2012). Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–99
- Shepherd J, Cobbe SM, Ford I, et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–7
- Shimada K, Mitamura K. (1994). Derivatization of thiol-containing compounds. J Chromatogr B Biomed Appl 659:227–41
- Tall AR. (1993). Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255–74